APOA1 and dementia: Despite a lack of current evidence supporting the use of lipid-lowering drugs in AD or other dementia, plasma levels of ApoA1 and TG/HDL-C appear to be a promising prognostic marker for the rate of cognitive decline in MCI and AD dementia subjects, and their therapeutic modification by diet and medication is likely to be an interesting opportunity in the near future [50].